The data, published Dec. 4, showed that all 34 participants who received the vaccine in Moderna’s phase 1 trial had antibodies that declined over time but remained high three months after receiving their second dose.
“These data give us further optimism to expect that the high level of efficacy recently demonstrated by mRNA-1273 to prevent COVID-19 disease will be durable,” Tal Zaks, MD, PhD, Moderna’s chief medical officer, said in a press release.
Moderna’s vaccine, called mRNA-1273, is administered in two shots 28 days apart. It will be reviewed by the FDA Dec. 17 and could receive emergency use authorization shortly thereafter.
More articles on pharmacy:
Pfizer vaccine approval could come this week, FDA adviser says
US needs price controls for COVID-19 drugs, employer advocacy group says
Dr. Slaoui to meet with Biden this week to talk vaccine distribution
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.